Table 2.

Cumulative average epoetin dosage and mortality HRs for weighted regression modelsa

U/wkPatient-MonthsNo. of Deaths% DeathsPrimary AnalysisSecondary Analysis ASecondary Analysis B
HR95% CIHR95% CIHR95% CI
<10,00041,1137761.90.900.52 to 1.540.560.38 to 0.821.210.79 to 1.83
10,000 to <20,00045,25111112.50.840.67 to 1.050.840.65 to to 1.55
20,000 to <30,000 (reference group)20,6827223.5ReferenceReferenceReference
30,000 to <40,00090703904.30.960.76 to 1.210.990.82 to 1.210.950.69 to 1.30
≥40,00097084995.10.910.67 to to 1.290.880.68 to 1.14
  • a The weighted models include baseline covariates (age, race, gender, underlying cause of ESRD, geographic region, Charlson index score, cardiovascular and noncardiovascular comorbidities, baseline hematocrit, average intravenous iron administered, length of inpatient stays in the baseline, and average epoetin dosage and number of administrations at baseline). Variables in the models to estimate weights include baseline covariates as listed above plus time-varying covariates including hematocrit, inpatient days, iron treatment, log epoetin dosage, and interaction terms between log epoetin dosage and time-varying hematocrit and between chains and both baseline epoetin dosage and time-varying epoetin dosage. Primary analysis: Epoetin was imputed for patients with a hospital stay >4 d on the basis of the previous outpatient epoetin prescription; secondary analysis A: Epoetin was imputed throughout duration of hospital stay; secondary analysis B: Epoetin was assumed not to be administered during hospital stay. Distribution of patient-months, number of deaths, and percentage death are based on primary analysis.